drugset
drugset / Trial / NCT01482949

A Rollover Protocol for Subjects Previously Treated With AGS-003

NCT01482949 ↗

Phase 2 Terminated 2 enrolled Argos Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate clinical response to AGS-003 alone or in combination with sunitinib therapy.

Timeline

Start
2011-09
Primary completion
2018-05
Completion
2018-05

Drugs

EvaluationDrugModalityDoseRoute
Subject ROCAPULDENCEL-T Cell therapy — —

Indications

renal cell carcinoma